Table 1 Demographics, disease characteristics and medications.
From: Self-management skills in adolescents with chronic rheumatic disease: A cross-sectional survey
| Â | N (%) | Mean (SD) or Median (Range) |
|---|---|---|
Gender | Â | Â |
   Male | 11 (21%) |  |
   Female | 41 (79%) |  |
Mean age (SD)# | Â | 15.9 (2.1) |
   Race/Ethnicity |  |  |
   Caucasian | 26 (50%) |  |
   Asian | 12 (23%) |  |
   Latino | 4 (8%) |  |
   African American | 3 (6%) |  |
   Other/Unknown | 7 (13%) |  |
Diagnosis | Â | Â |
   Juvenile Idiopathic Arthritis | 23 (44%) |  |
Oligoarthritis | 1 (2%) | Â |
Rheumatoid factor positive polyarthritis | 3 (6%) | Â |
Rheumatoid factor negative polyarthritis | 8 (15%) | Â |
Systemic arthritis | 8 (15%) | Â |
Enthesitis-related arthritis | 2 (4%) | Â |
Psoriatic arthritis | 1 (2%) | Â |
   Systemic Lupus Erythematosus | 18 (35%) |  |
   Juvenile Dermatomyositis | 4 (8%) |  |
   Mixed Connective Tissue Disease | 3 (6%) |  |
   Scleroderma | 2 (4%) |  |
   Idiopathic Thrombocytopenic Purpura | 1 (2%) |  |
   Periodic Fever Syndrome | 1 (2%) |  |
Median Disease Duration (Range)# | Â | 5.3 (0-15) |
Mean Self-Reported Disease Activity (SD)* | Â | 4.1 (2.6) |
Medications | Â | Â |
   Corticosteroids | 30 (58%) |  |
   Methotrexate or Leflunomide | 24 (45%) |  |
   Hydroxychloroquine | 19 (37%) |  |
   Biologic | 15 (29%) |  |
   Immunosuppressant+ | 13 (25%) |  |
   Intravenous Immunoglobulin | 2 (4%) |  |
   Non-Steroidal Anti-Inflammatory Drug | 2 (4%) |  |